Ariane Sternberg, Dwight L. McKee and Cord Naujokat* Pages 1423 - 1433 ( 11 )
Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular machines for viral host cell entry, genome replication and protein processing. Such machinery encompasses SARS-CoV-2 envelope spike (S) glycoprotein required for host cell entry by binding to the ACE2 receptor, viral RNA-dependent RNA polymerase (RdRp) and 3-chymotrypsin-like main protease (3Clpro/Mpro). Under the pressure of the accelerating COVID-19 pandemic caused by the outbreak of SARS-CoV-2 in Wuhan, China in December 2019, novel and repurposed drugs were recently designed and identified for targeting the SARS-CoV-2 reproduction machinery, with the aim to limit the spread of SARS-CoV-2 and morbidity and mortality due to the COVID-19 pandemic.
Coronavirus SARS-CoV-2, COVID-19, S protein, RNA polymerase, 3Clpro, Camostat, Remdesivir, α-Ketoamides.
Center and Network for Targeted Oncology, Muehlackerweg 8, D-69239 Heidelberg, Integrative Cancer Consulting, Aptos, CA, Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D-69120 Heidelberg